Read more VitroScan @ESGO Congress 2026 – Meet us in Copenhagen! 🌍

12 February 2026

We’re delighted to share that Willemijn Vader, VitroScan’s CEO, together with Michelle Meijer, member of our Project Steering Committee, will be attending the ESGO 2026 Congress in Copenhagen.

Read more

Read more Meet VitroScan at BioEurope Spring 2026

9 February 2026

Exciting news! VitroScan will be at BioEuropeSpring (March 23‑25, Lisbon). We’d love to connect and discuss how our ex vivo micro‑tumor testing can accelerate the development of your oncology assets.

Read more

Read more Biotech Booster Annual Event 2026 on March 10: Willemijn Vader and Joris Schuurmans will present ChemoPredict project journey

5 February 2026

Join Willemijn Vader, CEO at VitroScan, and Joris Schuurmans, Chair of the ChemoPredict project steering committee, at the Biotech Booster Annual Event on March 10.

Read more

Read more Info Sheet ADC efficacy assessment

1 December 2025

Download our Info sheet on ADC efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Info Sheet Bispecific antibody testing

1 December 2025

Download our Info sheet on bispecific antibody efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Our latest publication at a glance!

1 October 2025

Download our Info sheet on the latest VitroScan publication highlighting the predictive value of our platform

Read more

Read more VitroScan at SITC 2025

5 November 2025

Download our poster: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab

Read more

Read more VitroScan at ENA 2025

22 October 2025

Download our poster: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer

Read more

Read more VitroScan at ESMO 2025

17 October 2025

Download our poster: Chemo Sensitivity Score using an ex vivo 3D micro-tumor testing platform to predict clinical response to platinum-based therapy in patients with high-grade serous ovarian cancer

Read more

Read more Koedoot et al., npj Precision Oncology, 2025

30 August 2025

Publication of our study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.

Read more